EPS growth is an important number as it indicates the future prospects of Compugen. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 30525.00 % over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Compugen.
Compugen is in the healthcare sector and is in the biotechnology industry. The company CEO is Anat Cohen Dayag. Compugen is a therapeutic discovery company. The Company’s pipeline consists of early-stage immuno-oncology programs aimed at harnessing the immune system to fight cancer.
Previous Intraday Performance:
The CGEN shares had a previous change of 0.58% which opened at 3.41 and closed at 3.46. It moved to an intraday high of 3.55 and a low of 3.35.
SeekingAlpha: Bristol-Myers’ Collaboration Deal: Accelerating Potential Creation Value For Compugen Ltd.
Historical Performance:
Over the last five trading days, CGEN shares returned 6.46% and in the past 30 trading days it returned -4.95%. Over three months, it changed -7.73%. In one year it has changed 34.37% and within that year its 52-week high was 5.00 and its 52-week low was 2.25. CGEN stock is 53.78% above its 52 Week Low.
Our calculations result in a 200 day moving average of 3.60 and a 50 day moving average of 3.39. Right now, CGEN stock is trading -3.93% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
SeekingAlpha: Bristol-Myers’ Collaboration Deal: Accelerating Potential Creation Value For Compugen Ltd.
Liquidity:
The company has a market cap of $197.9m with 57.2m shares outstanding and a float of 57.2m shares. Trading volume was 132,560 shares and has experienced an average volume of 154,328 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Compugen was -0.72 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.12.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.05
06-30-2018: -0.19
03-31-2018: 0
12-31-2017: -0.18
Indicators Also to Watch:
Based on the latest filings, there is 14.50% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.38
SeekingAlpha: Tracking Wallace Weitz’s Weitz Investment Management Portfolio – Q3 2018 Update
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -59.41%, return on assets is -46.11%, price-to-sales is 11.05 and price-to-book is 5.19.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Biotechnology, CGEN, Compugen, Healthcare
